Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: Response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): Study protocol of a phase II, open-label, multicenter study

Bernies van der Hiel*, John B A G Haanen, Marcel P M Stokkel, Daniel S. Peeper, Connie R. Jimenez, Jos H Beijnen, Bart A. van de Wiel, Ronald Boellaard, Alfons J M van den Eertwegh, H. van Tinteren, Lodewyk F A Wessels, Martijn P J K Lolkema, Otto S Hoekstra, Geke A P Hospers, Adrienne H Brouwers, R.H.T. Koornstra, A. I. J. Arens, F. Y.F.L. de Vos, M. G.G. Hobbelink, H. W. KapiteijnL. F. de Geus-Oei, W. H.J. Kruit, F.J. Verzijlbergen, M. J.B. Aarts, F. M. Mottaghy, J. W.B. de Groot, S. Knollema, D. Piersma, A. Agool, Art Vreugdenhil, I H Liem, Franchette W P J van den Berkmortel, M.W. Schreurs,

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Fingerprint

Dive into the research topics of 'Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: Response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): Study protocol of a phase II, open-label, multicenter study'. Together they form a unique fingerprint.

Biochemistry, Genetics and Molecular Biology

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry